Logo image of IPA

IMMUNOPRECISE ANTIBODIES LTD (IPA) Stock Fundamental Analysis

USA - NASDAQ:IPA - CA45257F2008 - Common Stock

2.07 USD
+0.14 (+7.25%)
Last: 9/3/2025, 8:24:29 PM
2.12 USD
+0.05 (+2.42%)
After Hours: 9/3/2025, 8:24:29 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to IPA. IPA was compared to 57 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of IPA have multiple concerns. IPA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

IPA had negative earnings in the past year.
In the past year IPA has reported a negative cash flow from operations.
IPA had negative earnings in each of the past 5 years.
In the past 5 years IPA always reported negative operating cash flow.
IPA Yearly Net Income VS EBIT VS OCF VS FCFIPA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M

1.2 Ratios

IPA has a Return On Assets of -68.03%. This is amonst the worse of the industry: IPA underperforms 89.09% of its industry peers.
The Return On Equity of IPA (-127.97%) is worse than 83.64% of its industry peers.
Industry RankSector Rank
ROA -68.03%
ROE -127.97%
ROIC N/A
ROA(3y)-49.16%
ROA(5y)-35.25%
ROE(3y)-84.68%
ROE(5y)-57.83%
ROIC(3y)N/A
ROIC(5y)N/A
IPA Yearly ROA, ROE, ROICIPA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150 -200

1.3 Margins

Looking at the Gross Margin, with a value of 55.25%, IPA is in the better half of the industry, outperforming 65.45% of the companies in the same industry.
In the last couple of years the Gross Margin of IPA has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for IPA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 55.25%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.87%
GM growth 5Y-0.67%
IPA Yearly Profit, Operating, Gross MarginsIPA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150 -200

More info and screens

2

2. Health

2.1 Basic Checks

IPA does not have a ROIC to compare to the WACC, probably because it is not profitable.
IPA has more shares outstanding than it did 1 year ago.
The number of shares outstanding for IPA has been increased compared to 5 years ago.
IPA has a worse debt/assets ratio than last year.
IPA Yearly Shares OutstandingIPA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
IPA Yearly Total Debt VS Total AssetsIPA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

2.2 Solvency

IPA has an Altman-Z score of -0.35. This is a bad value and indicates that IPA is not financially healthy and even has some risk of bankruptcy.
IPA has a worse Altman-Z score (-0.35) than 76.36% of its industry peers.
A Debt/Equity ratio of 0.49 indicates that IPA is not too dependend on debt financing.
IPA has a Debt to Equity ratio of 0.49. This is in the lower half of the industry: IPA underperforms 63.64% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF N/A
Altman-Z -0.35
ROIC/WACCN/A
WACC10.11%
IPA Yearly LT Debt VS Equity VS FCFIPA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 2.08 indicates that IPA has no problem at all paying its short term obligations.
IPA has a Current ratio (2.08) which is comparable to the rest of the industry.
IPA has a Quick Ratio of 1.85. This is a normal value and indicates that IPA is financially healthy and should not expect problems in meeting its short term obligations.
IPA has a Quick ratio of 1.85. This is comparable to the rest of the industry: IPA outperforms 47.27% of its industry peers.
Industry RankSector Rank
Current Ratio 2.08
Quick Ratio 1.85
IPA Yearly Current Assets VS Current LiabilitesIPA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 34.78% over the past year.
Looking at the last year, IPA shows a small growth in Revenue. The Revenue has grown by 0.01% in the last year.
The Revenue has been growing by 11.77% on average over the past years. This is quite good.
EPS 1Y (TTM)34.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.55%
Revenue 1Y (TTM)0.01%
Revenue growth 3Y8.19%
Revenue growth 5Y11.77%
Sales Q2Q%8.08%

3.2 Future

The Earnings Per Share is expected to grow by 39.31% on average over the next years. This is a very strong growth
IPA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.92% yearly.
EPS Next Y49.5%
EPS Next 2Y48.39%
EPS Next 3Y35.81%
EPS Next 5Y39.31%
Revenue Next Year13.46%
Revenue Next 2Y22.45%
Revenue Next 3Y19.46%
Revenue Next 5Y17.92%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IPA Yearly Revenue VS EstimatesIPA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 20M 40M 60M
IPA Yearly EPS VS EstimatesIPA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 0.5 -0.5 1 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IPA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IPA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IPA Price Earnings VS Forward Price EarningsIPA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IPA Per share dataIPA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2

4.3 Compensation for Growth

A more expensive valuation may be justified as IPA's earnings are expected to grow with 35.81% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y48.39%
EPS Next 3Y35.81%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IPA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMMUNOPRECISE ANTIBODIES LTD

NASDAQ:IPA (9/3/2025, 8:24:29 PM)

After market: 2.12 +0.05 (+2.42%)

2.07

+0.14 (+7.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)09-11 2025-09-11
Earnings (Next)12-08 2025-12-08
Inst Owners8.61%
Inst Owner Change0%
Ins Owners1.19%
Ins Owner ChangeN/A
Market Cap95.53M
Analysts80
Price Target5.1 (146.38%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)44.31%
Min EPS beat(2)0.99%
Max EPS beat(2)87.62%
EPS beat(4)3
Avg EPS beat(4)14.95%
Min EPS beat(4)-35.01%
Max EPS beat(4)87.62%
EPS beat(8)6
Avg EPS beat(8)14.05%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-9.96%
Min Revenue beat(2)-12.4%
Max Revenue beat(2)-7.52%
Revenue beat(4)0
Avg Revenue beat(4)-12.13%
Min Revenue beat(4)-22.81%
Max Revenue beat(4)-5.81%
Revenue beat(8)3
Avg Revenue beat(8)-4.97%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)25%
PT rev (3m)25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-10%
EPS NY rev (1m)-36.36%
EPS NY rev (3m)-36.36%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.34%
Revenue NY rev (1m)-0.6%
Revenue NY rev (3m)-0.6%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.4
P/FCF N/A
P/OCF N/A
P/B 5.6
P/tB 9.23
EV/EBITDA N/A
EPS(TTM)-0.22
EYN/A
EPS(NY)-0.11
Fwd EYN/A
FCF(TTM)-0.11
FCFYN/A
OCF(TTM)-0.1
OCFYN/A
SpS0.38
BVpS0.37
TBVpS0.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -68.03%
ROE -127.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 55.25%
FCFM N/A
ROA(3y)-49.16%
ROA(5y)-35.25%
ROE(3y)-84.68%
ROE(5y)-57.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.87%
GM growth 5Y-0.67%
F-Score4
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.61%
Cap/Sales 3.26%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.08
Quick Ratio 1.85
Altman-Z -0.35
F-Score4
WACC10.11%
ROIC/WACCN/A
Cap/Depr(3y)20.78%
Cap/Depr(5y)25.53%
Cap/Sales(3y)5.4%
Cap/Sales(5y)5.87%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.55%
EPS Next Y49.5%
EPS Next 2Y48.39%
EPS Next 3Y35.81%
EPS Next 5Y39.31%
Revenue 1Y (TTM)0.01%
Revenue growth 3Y8.19%
Revenue growth 5Y11.77%
Sales Q2Q%8.08%
Revenue Next Year13.46%
Revenue Next 2Y22.45%
Revenue Next 3Y19.46%
Revenue Next 5Y17.92%
EBIT growth 1Y12.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-27.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-50.97%
OCF growth 3YN/A
OCF growth 5YN/A